Prevention of Rh-haemolytic Disease: Final Results of the “High-risk” Clinical Trial: A COMBINED STUDY FROM CENTRES IN ENGLAND AND BALTIMOREBr Med J 1971; 2 doi: https://doi.org/10.1136/bmj.2.5762.607 (Published 12 June 1971) Cite this as: Br Med J 1971;2:607
The final results are reported of a trial of about 1,000 μg of anti-D gammaglobulin given intramuscularly to a selected high-risk group of Rh-negative primiparae just delivered of an ABO-compatible Rh-positive baby, the aim being to prevent them becoming immunized to Rh. Six months after delivery only 1 out of 173 treated mothers had been immunized as against 38 out of 176 controls. The crucial test of the prophylactic therapy depends on the presence or otherwise of anti-D at the end of a second Rh-positive pregnancy. Of 86 treated mothers two had antibodies at this time compared with 20 out of 65 controls.
The results show a high degree of protection in this group of mothers.
↵* From the Nuffield Unit of Medical Genetics, Department of Medicine, University of Liverpool; the Sheffield Regional Blood Transfusion Service; the Leeds Regional Transfusion Laboratory; the Baltimore City Hospitals.